The seminal TAILOR-X prospective trial of over 10,000 women with node-negative, HR+, and HER2- breast cancer demonstrated the utility of incorporating a RS into the patient’s treatment paradigm in order to identify those who are unlikely to benefit from adjuvant chemotherapy in addition to endocrine therapy. The gene discussed is ERBB2; the disease is breast cancer.